Pfizer Anticipates ‘Fair’ Share Of Adalimumab Market In US
Company Expects To Use Interchangeability Designation To Its Advantage
Executive Summary
Pfizer expects to make significant strides in the adalimumab market once it launches its Humira biosimilar late next year, but may not be able to enjoy its anticipated interchangeability designation until 2024.
You may also be interested in...
Interchangeable Exclusivity: Pfizer To Rival Boehringer On Humira Biosimilar After US FDA Decision
FDA decision ends Boehringer Ingelheim’s exclusivity for interchangeable biosimilar of Humira after just a few months. Pfizer reveals pricing and launch information for its Abrilada version of adalimumab.
FDA Decision On Interchangeable Exclusivity Allows Pfizer To Rival Boehringer On Adalimumab
An FDA decision around the timing of first interchangeable biosimilar exclusivity has brought to an end Boehringer Ingelheim’s time on the market with a unique interchangeable Humira rival, with the agency also granting interchangeability for Pfizer’s Abrilada version of adalimumab.
Will Pfizer’s Biosimilars Hit $2bn Again In 2023?
While Pfizer has for a couple of years now brought in annual global biosimilars turnover of more than $2bn, half-year sales suggest this may not be a sure thing in 2023 – although the firm’s strategy on adalimumab in the US could play a decisive role.